Abstract
Recent studies indicated that inflammation at atherosclerotic arteries of the heart contribute greatly to the rapid development of myocardial infarct. As one marker to estimate the degree of inflammation on any part of the body, including the heart, C-Reactive Protein (CRP) can be used to estimate presence of inflammation. Similarly, to estimate general cardio-vascular condition it has been well known that abnormal increase in L-homocystinc can be used as a very important cardio-vascular risk marker (factor), and it is also considered to be a risk factor for Alzheimer’s disease when it’s increased significantly. In addition, when there is myocardial tissue damage, both cardiac Troponin T (cTn T) and cardiac Troponin I (cTn I) are released from damaged heart tissue, but without laboratory test for clinical diagnosis of myocardial infarct, the presence of persistent chest pain of more than 15 minutes can be considered as having myocardial infarct. But in only about half of the patients, electrocardiogram will show sign of myocardial ischemia or with elevated ST segment or infarct with pathological Q wave, but about half of the patients with chest pain may not show any significant distinctive ECG abnormality indicating myocardial infarct. However, about 3 hours after the onset of myocardial infarct, cardiac Troponin T will increase significantly in blood test and about 4 hours after onset of myocardial infarct, cardiac Troponin I will increase in the blood test. Also, increase in cardiac Troponin T will last much longer than cardiac Troponin I. Because of this reason cardiac Troponin T is often used clinically more than cardiac Troponin I for a blood test as a myocardial infarct marker, in spite of the fact that cardiac Troponin I is specifically due to heart muscle damage while cardiac Troponin T can be increased not only by heart muscle damage, but also damage to the muscles other than the heart as well as kidney disease. In order to evaluate the critical amounts above which indicates the presence of abnormal condition, these critical values were determined non-invasively for CRP, L-homocystine, cardiac Troponin T and cardiac Troponin I, using Bi-Digital O-Ring Test Resonance Phenomena between 2 identical substances, namely between Reference Control Substance with known, exact amount and between the same molecule existing inside of the body. These critical values were found to be as follows: CRP =3ng, L-homocystine =3mg, cardiac Troponin T=3ng, cardiac Troponin I=3ng. These cardiovascular and inflammatory markers are relatively proportional to each other whenever one of them is abnormal. Since with Bi-Digital O-Ring Test, we can detect any minute changes locally before significant blood changes appear, we have been using cardiac Troponin I for screening of heart disease and other markers are often used to obtain supplemental information. In order to perform a screening test, 3ng of cardiac Troponin I was used as a reference control substance, and 3rd person in the indirect Bi-Digital O-Ring Tests holds this reference control substance in the hand opposite to the hand used for Bi-Digital O-Ring Test by satisfying the 3 basic requirements which are necessary for person to perform reproducible Bi-Digital O-Ring Test. The third person, while holding both the 3ng of cardiac Troponin I, with red spectrum laser beam of about 1-5mW with wavelength of 560-670nm, projects the laser beam on patient to be examined. The patient extends his arms out to the side with the exposed hands raised above the head, bent at the elbow, with palms facing towards the examiner. The patient exposes the base of front of the neck at supra manubrium stemi (at CV22), exposes his thigh as close to the inguinal area as possible, and also exposes the Umbilicus. When O-Ring Test produces a 0-2 opening (0- -2), it is considered to be within normal limit. If 3 O-Ring opens (-3), it is considered to be borderline. When 4 or more O-Ring opens (-4, -5, -, etc), it is considered to be heart disease risk factor positive, and the higher the minus value, then the more abnormal the disease. Using this method, the author often found that when the person had a Supra-Ventricular Arrhythmia, then usually the right hand is minus 6 (-6) and supra manubrium stemi is minus 6 (-6) and left hand is minus 4 (-4) or minus 5 (-5), while the Umbilicus and thigh are minus 2 or minus 1 (-2 or -1). However, if there is an additional problem on the left ventricle, then the left arm also becomes minus 5 or 6 (-5, or 6), depending on the degree of abnormality of the left ventricle. These exact locations of the abnormality can be localized accurately by X-, Y-axis laser line screening of the upper part of the body, since cardiac Troponin I is only increased in the presence of heart muscle damage. By drawing any strong positive resonance line for the X-axis and Y-axis, some or all of the crossing points show strong abnormal areas. Thus the center of the most abnormal area can be localized. The actual abnormal area involved surrounding these positive crossing points is then localized using a metal electrode and can be directly mapped on the chest wall with non-toxic magic ink. As a treatment, using Bi-Digital O-Ring Test, one can quickly identify which infection is causing these abnormalities. So far, the most common abnormalities found on the heart include the following: 1) Chlamydia Trachomatis; 2) Chlamydia Pneumoniae; 3) Mycobacterium Tuberculosis; 4) Cytomegalovirus; 5) Herpes Simplex Virus type 1; 6) Human Herpes Virus Type 6; 7) Helicobacter Pylori; etc. Once it is determined which virus and bacteria are present, then the amount of each virus or bacterium is measured quantitatively. Based on the degree of the strongest infection, priority is given for the strongest infection first. In treating a multiple infection, if the most effective medications are compatible with other effective anti-viral and anti bacterial agents, and then all of the compatible antibacterial and antiviral agents can be given simultaneously. If inhibition exists because of drug interaction, the most strong infection is treated first. But just giving effective medication cannot treat these infections in the heart effectively. With the application of the Selective Drug Uptake Enhancement Method (which was originally discovered by Omura Y. in 1990), it is possible to deliver the drug selectively to the pathological area most effectively, while drastically reducing drug uptake to the normal part of the body, by stimulating accurate organ representation area of the hands, corresponding to the pathological area of the heart (palm side of the 3rd segment of the middle finger) at same side as diseased area, using the organ representation map made by the author in the 1990s (published by Ido-No-Nippon Sha Tokyo, Japan, as well as by more updated revised edition by the author).
(This research is supported by Heart Disease Research Foundation of U.S.A, and ORT Life Science Research Institute of Japan).
Get full access to this article
View all access options for this article.